伊曲康唑结构式
|
常用名 | 伊曲康唑 | 英文名 | Itraconazole |
---|---|---|---|---|
CAS号 | 84625-61-6 | 分子量 | 705.633 | |
密度 | 1.4±0.1 g/cm3 | 沸点 | 850.0±75.0 °C at 760 mmHg | |
分子式 | C35H38Cl2N8O4 | 熔点 | 166°C | |
MSDS | 中文版 美版 | 闪点 | 467.9±37.1 °C | |
符号 |
GHS07 |
信号词 | Warning |
伊曲康唑用途伊曲康唑是一种三唑类抗真菌药.IC50价值:N /靶点:抗真菌药物:伊曲康唑在药理学上不同于其他唑类抗真菌药物,因为它是该类中唯一一种抑制hedgehog信号通路和血管生成的抑制剂。这些不同的活性与抑制细胞色素P450羊毛甾醇14α-脱甲基酶无关,并且确切的分子靶标仍然未被鉴定。功能上,伊曲康唑的抗血管生成活性已被证明与抑制糖基化,VEGFR2磷酸化和胆固醇生物合成途径有关。证据表明,伊曲康唑抑制hedgehog信号传导的结构决定因素与抗血管生成活性相关。体内:9名志愿者每天口服200mg伊曲康唑或配对安慰剂,持续4天。在第4天,与安慰剂相相比,伊曲康唑使咪达唑仑浓度 - 时间曲线下的面积从10倍增加到15倍(p <0.001),平均峰值浓度增加3到4倍(p <0.001)。在精神运动试验中,相互作用在药物给药后至少6小时具有统计学意义(p <0.05)。伊曲康唑对细胞色素P450IIIA的抑制作用可以解释观察到的药代动力学相互作用[4]。 |
中文名 | 伊曲康唑 |
---|---|
英文名 | itraconazole |
中文别名 | 4-[4-[4-[4-[[cis-2-(2,4-二氯苯基)-2-(1H-1,2,4-三唑-1-基甲基)-1,3-二氧戊环-4-基]甲氧基]苯基]哌嗪-1-基]苯基]-2-[(1RS)-1-甲基丙基]-1,2,4-三唑-3-酮 | 依他康唑 | 斯皮仁诺 | 亚特那唑 | 4-[4-[4-[4-[[2-(2,4-二氯苯基)-2-(1H-1,2,4-三唑-1-基甲基)-1,3-二氧戊环-4-基]甲氧基]苯基]-1-哌嗪基]苯基]-2,4-二氢-2-(1-甲基丙基)-3H-1,2,4-三唑-3-酮 |
英文别名 | 更多 |
描述 | Itraconazole是抗真菌剂。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.4±0.1 g/cm3 |
---|---|
沸点 | 850.0±75.0 °C at 760 mmHg |
熔点 | 166°C |
分子式 | C35H38Cl2N8O4 |
分子量 | 705.633 |
闪点 | 467.9±37.1 °C |
精确质量 | 704.239319 |
PSA | 104.70000 |
LogP | 4.35 |
外观性状 | 灰白色结晶固体 |
蒸汽压 | 0.0±3.2 mmHg at 25°C |
折射率 | 1.678 |
储存条件 | 2-8°C |
稳定性 | Stable. Incompatible with strong oxidizing agents. |
水溶解性 | chloroform: 50 mg/mL, clear, colorless |
分子结构 | 1、 摩尔折射率:189.33 2、 摩尔体积(cm3/mol):502.0 3、 等张比容(90.2K):1372.7 4、 表面张力(dyne/cm):55.9 5、 极化率(10-24cm3):75.05 |
更多 | 1.性状:从甲苯中结晶 2.熔点(ºC):166.2 3.溶解性:几乎不溶于水和稀酸溶液。 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302-H315-H319-H335 |
警示性声明 | P261-P305 + P351 + P338 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
危害码 (欧洲) | Xi:Irritant |
风险声明 (欧洲) | R36/37/38 |
安全声明 (欧洲) | S22-S26-S36 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | XZ5481000 |
海关编码 | 2934999090 |
~46% 伊曲康唑 84625-61-6 |
文献:Heeres; Backx; Van Cutsem Journal of Medicinal Chemistry, 1984 , vol. 27, # 7 p. 894 - 900 |
伊曲康唑上游产品 1 | |
---|---|
伊曲康唑下游产品 0 |
从间二氯苯出发,经和酮康唑完全相似的反应可得到化合物(I)。化合物(Ⅰ)再和1-乙酰基-4-(4-羟基苯基)哌嗪缩合,接着水解脱去乙酰基,和对硝基氯苯缩合,氢化还原,氯甲酸酯酰化,然后和水合肼反应后再环合,烷基化得伊曲康唑。其中间体1-乙酰基-4-(4-羟基苯基)哌嗪可以哌嗪为原料,经下面的反应来制备。
海关编码 | 2934999090 |
---|---|
中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking.
Autophagy 10(7) , 1241-55, (2014) Glioblastoma is one of the most aggressive human cancers with poor prognosis, and therefore a critical need exists for novel therapeutic strategies for management of glioblastoma patients. Itraconazol... |
|
Antifungal susceptibility and virulence attributes of animal-derived isolates of Candida parapsilosis complex.
J. Med. Microbiol. 63(Pt 11) , 1568-72, (2014) This study aimed to identify strains of the Candida parapsilosis complex isolated from animals, as well as to assess their in vitro antifungal susceptibility profile and in vitro production of virulen... |
|
European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe.
Eur. J. Clin. Microbiol. Infect. Dis. 33(9) , 1623-30, (2014) In order to better understand the epidemiology of fusariosis in Europe, a survey collecting information on the clinical characteristics of the patients infected by Fusarium as well as on the infecting... |
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one |
Itrizole |
Candistat |
3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)- |
Sporanos |
2-sec-Butyl-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one |
2-sec-Butyl-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-1-piperazinyl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one |
2-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-on |
MFCD08064196 |
Itrac |
Cladosal 100 |
Canditral |
(±)-1-sec-Butyl-4-[p-[4-[p-[[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-d2-1,2,4-triazolin-5-one |
4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one |
4-{4-[4-(4-{[(2R,4S)-2-(2,4-Dichlorphenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-on |
4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one |
Itraconazole |